Clinical Trials
35 trialsNCT03554707 2026-05-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT04481204 2026-05-04
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT01847495 2024-10-04
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Wake Forest University Health Sciences
Phase NA Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04943627 2022-10-05
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
Phase 3 Withdrawn
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT03110510 2022-06-15
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Withdrawn
NCT05042934 2022-02-10
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05177276 2022-01-04
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT04543916 2021-03-03
Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Virginia Commonwealth University
Phase 1/2 Withdrawn
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT02747537 2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
Phase 2 Withdrawn
NCT03161574 2019-08-08
FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
Guangxi Medical University
Phase 2 Withdrawn
NCT03069950 2019-05-21
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT00577109 2018-07-31
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 2 Withdrawn
NCT03222089 2018-03-27
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Fujian Cancer Hospital
Phase 2 Withdrawn
NCT02720601 2018-01-25
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT02046538 2017-01-25
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT02573220 2016-12-09
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
University of Chicago
Phase 1 Withdrawn
NCT01473303 2016-06-28
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT02575508 2016-05-20
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT01631539 2014-12-04
Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
Universitaire Ziekenhuizen KU Leuven
Phase NA Withdrawn
NCT01939483 2014-10-08
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
University of California, Irvine
Phase NA Withdrawn
NCT01941173 2014-07-21
Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
City of Hope Medical Center
Phase NA Withdrawn
NCT02055196 2014-06-02
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT01654081 2014-05-30
A Protocol of Irinotecan for Carcinoma of the Lung
University of Kentucky
Phase 2 Withdrawn
NCT01605344 2014-02-27
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
UNC Lineberger Comprehensive Cancer Center
Phase 1 Withdrawn
NCT01070290 2014-01-07
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Withdrawn
NCT01293942 2013-06-05
IXO+A in mCRC With Liver-only Metastases
Ottawa Hospital Research Institute
Phase 2 Withdrawn
NCT00766220 2013-01-03
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00070434 2012-06-07
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00233623 2011-01-27
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
AstraZeneca
Phase 2 Withdrawn
NCT00209612 2009-02-17
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Withdrawn